Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Active Not Recruiting Phase 1 Trials for Zandelisib (DB18245)

IndicationStatusPhase
DBCOND0120608 (Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03985189Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaTreatment